Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Abroad (travel likely)Recruiting

Conditions

Lung Cancer · Breast Cancer · Kidney Cancer · Bladder Cancer · Gastric Cancer · Skin Cancer · Melanoma · Head Neck Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Roberto Iacovelli, Roma, Italy
Contact: Study coordinator (Roberto Iacovelli, Prof) · roberto.iacovelli@policlinicogemelli.it · +390630157373
Contact: Principal Investigator (Roberto Iacovelli)

Study leads

Roberto Iacovelli
Principal Investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer · Tumor, Solid · Malignant Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Austin, United States · Irving, United States

Prospective Urban Rural Epidemiology Study

Cardiovascular Diseases · Risk Factor, Cardiovascular · Health Behavior

Abroad (travel likely)Recruiting

Rosario, Argentina · Dhaka, Bangladesh

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Pan-tumor MRD Study

Muscle Invasive Bladder Urothelial Carcinoma · Esophageal Cancer · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Abroad (travel likely)Recruiting

San Diego, United States · Maumee, United States